Phaseline

Companies › China Immunotech (Beijing) Biotechnology

China Immunotech (Beijing) Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 6 Phase 1; Hematology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YTS109 cells
STAR-T cell therapy
–Phase 1Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Systemic Lupus ErythematosusNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06943937YTS109 cellsPhase 1Lupus Nephritis (LN)HematologyApr 2026
NCT07236801YTS109 cellsPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyNov 2026
NCT07236762YTS109 cellsPhase 1Systemic Lupus ErythematosusImmunologyNov 2026
NCT06978647YTS109 cellsPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyMay 2027
NCT07123519YTS109 cellsPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyAug 2027
NCT07104721YTS109 cellsPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.